Status:
COMPLETED
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Lead Sponsor:
Allergy Therapeutics
Conditions:
Rhinitis, Allergic
Respiratory Tract Infections
Eligibility:
All Genders
18+ years
Brief Summary
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or gras...
Detailed Description
In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tr...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years
- Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grass and/or tree pollen
- completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts or their mixtures according to SMPC effective during immunotherapy
Exclusion
- Contraindication according to Summary of Product Characteristics (SMPC) effective during immunotherapy
- no additional allergen-specific immunotherapy with another product than Pollinex Quattro
Key Trial Info
Start Date :
April 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 5 2020
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT04389034
Start Date
April 22 2020
End Date
October 5 2020
Last Update
February 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Outpatient Center Dr Stollewerk/Niebecker
Cologne, Germany